

Original article

The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink

Fiona A. Pearce¹, Matthew J. Grainge¹, Peter C. Lanyon², Richard A. Watts³ and Richard B. Hubbard¹

Abstract

Objective. To estimate the incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK.

Methods. We conducted a historical cohort study using data from the Clinical Practice Research Datalink and Hospital Episode Statistics (HES). We calculated incidence rate ratios, adjusted for age, gender and ethnicity, using Poisson regression.

Results. We identified 462 cases diagnosed between 1997 and 2013. Our overall estimate of incidence was 11.8 (95% CI: 10.7, 12.9)/million person-years. The incidence was 0.88 (95% CI: 0.40, 1.96) in children (aged <16 years) and 14.0 (95% CI: 12.8, 15.4) in adults. The incidence was lower in females (adjusted incidence rate ratio = 0.68; 95% CI: 0.56, 0.81) and highest in the 55–69 year age group (adjusted incidence rate ratio = 6.8, 95% CI: 4.9, 9.6; reference group 16–39 years). The incidence was not significantly different in the Black/Minority Ethnic population from that in the White population (adjusted odds ratio = 0.78, 95% CI: 0.53, 1.13, $P = 0.13$). The prevalence in 2013 was 134.9 (95% CI: 121.3, 149.6)/million. Mortality was 13.6% at 1-year, and higher in the HES- than in the Clinical Practice Research Datalink-identified cases (hazard ratio = 3.16, 95% CI: 2.19, 4.56, $P < 0.001$).

Conclusion. By combining primary and secondary care datasets, we have found the incidence and mortality of granulomatosis with polyangiitis to be higher than previously reported. We predict that at present each year in the UK there will be ~700 new cases, of whom 95 will die within 12 months.

Key words: ANCA-associated vasculitis, granulomatosis with polyangiitis, incidence, prevalence, mortality, epidemiology

Rheumatology key messages

- We estimate that the incidence of granulomatosis with polyangiitis in the UK is 11.8/million person-years.
- The incidence is similar in Black/Minority Ethnic and White populations, but the prevalence remains lower in Black/Minority Ethnic populations.
- The mortality among people with granulomatosis with polyangiitis is 14% at 1 year.

Introduction

Previous estimates of incidence and prevalence of granulomatosis with polyangiitis (GPA, formerly known

as Wegener's granulomatosis) vary widely and have mainly been from small studies with low numbers of cases [1]. In addition, there are few data on influence of ethnic group, gender and age on incidence.

To improve the evidence base, a large study is needed that captures the full spectrum of people with this illness. Studies of disease incidence based on hospital case series in specialist centres may miss the mildest and most severe cases, as they may never be referred to the specialist centre, or may die before referral can be arranged. Studies based in primary care have the potential to reduce such referral bias, but may miss the most

¹Division of Epidemiology and Public Health, University of Nottingham, ²Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham and ³Department of Rheumatology, Ipswich Hospital, Ipswich, UK

Submitted 24 June 2016; revised version accepted 12 October 2016

Correspondence to: Fiona Pearce, Division of Epidemiology and Public Health, B126, Clinical Sciences Building, City Hospital, University of Nottingham, Nottingham, NG5 1PB, UK.
E-mail: Fiona.Pearce@nottingham.ac.uk

severe cases that are diagnosed in hospital and die before accessing primary care services again. Ideally, a cohort is needed with case ascertainment in both primary and secondary care.

The aim of this study is to estimate the incidence, prevalence and mortality of GPA in a UK population-based cohort, using both general practitioner (GP) and hospital records contained within the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) datasets, during 1997–2013.

Patients and methods

Study design and study population

This is a historical cohort study containing the 398 practices in the CPRD with data linked to HES (~65% of patients in the whole CPRD). The CPRD is a longitudinal database of anonymized medical records from GPs. Patients are broadly representative of the UK population in terms of age, sex and ethnicity [2]. The HES contains records of all inpatient stays and day case attendances in England. Primary and secondary diagnoses from each admission are coded using the 10th revision of the World Health Organization International Statistical Classification of Diseases and Related Health Problems (ICD-10).

We included people contributing data to CPRD-HES between 1 April 1997 and 31 December 2013. Patients were eligible for periods of time where their CPRD records were deemed to be of acceptable standard for research by the CPRD [2].

Case definition

Cases had a diagnosis of GPA by either Read code in the CPRD or ICD-10 code in HES. To select relevant diagnosis codes, the Read code and ICD-10 dictionaries were searched using the terms GPA and the condition's former name, Wegener's granulomatosis. This identified only one relevant and specific code in each: Read code G754 and ICD-10 code M31.3, both for Wegener's granulomatosis. The Read code has previously been validated [3], and work had previously been undertaken locally to validate the ICD-10 code, as described in the Discussion. The diagnosis date was taken as first occurrence of a code for vasculitis or GPA in a patient with a CPRD or ICD-10 code for GPA, as we considered it unlikely that two types of vasculitis would co-exist in the same person. Incident cases had a first record of a code for GPA during the study period, and included only patients with at least 1 year of follow-up from practice registration prior to diagnosis to try to minimize the number of prevalent cases misclassified as incident [4]. The denominator was all the people who contributed research standard data to the CPRD-HES during the study dates [2].

Statistical analysis

We categorized age into groups (0–15, 16–39, 40–54, 55–69, 70–84, 85+ years). Self-reported ethnicity was coded according to the Office for National Statistics 5+1 categories (White, Mixed, Asian, Black, Chinese or other and unknown). In addition, to improve statistical

power, we recoded ethnicity as White vs Black and Minority Ethnic (BME) vs unknown. We also performed a sensitivity analysis by re-categorizing those with unknown ethnicity as White.

We calculated crude annual incidence rates/million person-years, and stratified these by age group, sex and ethnic group. Unadjusted incidence rate ratios (IRRs) were obtained by fitting variables individually in separate Poisson regression models. Mutually adjusted IRRs were obtained by fitting age, sex and ethnic group as *a priori* confounders in a single Poisson model. We calculated point prevalence/million people on 1 July 2013 and stratified this in the same way as for incidence. We used logistic regression to calculate odds ratios.

We used Kaplan–Meier methods to estimate survival in patients with GPA at pre-specified times following diagnosis (30, 90 days and 1 year) and stratified mortality rates by source of case identification (CPRD with or without a HES diagnosis vs identified by HES only), age, sex and ethnicity. We used Cox proportional hazards models to compare hazard ratios.

We used direct standardization of CPRD/HES age and sex-specific incidence rates to the age and sex-stratified UK population in 2016 [5], to estimate the number of expected incident cases in the UK, and applied our mortality estimate to predict how many would die within 12 months. We estimated prevalence from the total population of the UK in 2016. All analyses were performed using Stata 14 statistical software (Statacorp, TX, USA).

For purposes of comparison with the previous CPRD study [3], we re-ran our analyses using CPRD-only data (the whole of the CPRD, including those people from practices without linked HES data), which we report in a sensitivity analysis.

Ethics

Independent Scientific Advisory Committee for MHRA Database Research approval was obtained for this study on 21/07/2015 (protocol 15_150R).

Results


Overall, we identified 462 incident cases of GPA in CPRD-HES (see Fig. 1). The cohort had a slight male predominance (56.7% male) and mean (s.d.) age at diagnosis of 60.0 (15.9) years.

Incidence

We estimated the overall incidence rate to be 11.8 (95% CI: 10.7, 12.9)/million person-years based on 462 cases of GPA in 39 286 088 person-years of follow-up. The incidence in children (aged <16 years) was 0.88 (95% CI: 0.40, 1.96)/million person-years, and among adults (\geq 16 years) was 14.0 (95% CI: 12.8, 15.4)/million person-years.

Temporal trend

The incidence by year is shown in Table 1. The annual incidence in CPRD-HES appears to have increased

Fig. 1 Flow diagram of ascertainment of incident cases of granulomatosis with polyangiitis

Cases ascertained from the CPRD-HES. Acceptable patient records and periods where practices record up to standard data are quality standards for research devised by the CPRD. ^aIn order to exclude prevalent cases. CPRD: Clinical Practice Research Datalink; HES: Hospital Episode Statistics.

during the first few years of the study period, but there was no significant change from 2000 onwards (IRR/year 1.02, 95% CI: 0.99, 1.04, P -trend=0.2).

Age and gender

Crude incidence rates and adjusted rate ratios are presented in Table 2. Incidence was lower among women than among men, with adjusted IRR 0.67 (95% CI: 0.56, 0.81, $P < 0.001$). Peak age of incidence was at 55–69 years (IRR = 6.8, 95% CI: 4.9, 9.6, $P < 0.001$, compared with 16–39 years) and similar at 70–84 years (IRR = 6.4, 95% CI: 4.5, 9.1, $P < 0.001$, compared with 16–39 years).

Ethnicity

We identified ethnicity for 90.7% of cases of GPA, but only 76.8% of the denominator CPRD-HES-linked population (see supplementary Table S1, available at *Rheumatology* Online). The unknown denominator population was half as large as the White population, and three times the size of the BME population. Crude incidence was highest in the White ethnic group (16.2, 95% CI: 14.7, 17.9)/million person-years, intermediate in the BME group (7.9, 95% CI: 5.5, 11.3) and lowest in the group with unknown ethnicity (3.7, 95% CI: 2.8, 5.0). In analysis adjusted for age

TABLE 1 Annual incidence of granulomatosis with polyangiitis 1997–2013 per million person-years

Year	Person-years	Incident cases	Incidence rate (95% CI)
1997	871 999	8	9.2 (4.6, 18.3)
1998	1 269 386	6	4.7 (2.1, 10.5)
1999	1 580 708	11	7.0 (3.9, 12.6)
2000	1 959 570	20	10.2 (6.6, 15.8)
2001	2 152 646	18	8.4 (5.3, 13.3)
2002	2 359 964	27	11.4 (7.8, 16.7)
2003	2 464 465	33	13.4 (9.5, 18.8)
2004	2 548 038	23	9.0 (6.0, 13.6)
2005	2 625 711	34	12.9 (9.3, 18.1)
2006	2 684 390	33	12.3 (8.7, 17.3)
2007	2 747 254	38	13.8 (10.1, 19.0)
2008	2 776 129	39	14.0 (10.3, 19.2)
2009	2 801 004	42	15.0 (11.1, 20.3)
2010	2 760 640	38	13.8 (10.0, 18.9)
2011	2 674 883	33	12.3 (8.8, 17.4)
2012	2 602 133	29	11.1 (7.7, 16.0)
2013	2 408 704	30	12.5 (8.7, 17.8)

Cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES). Overall incidence=462 cases in 39 286 088 person-years of follow-up, giving an incidence rate of 11.8 (95% CI: 10.7, 12.9).

and sex, the results were similar but slightly attenuated: the IRR for BME compared with Whites was 0.64 (95% CI: 0.44, 0.94) and for people of unknown ethnicity compared with Whites was 0.30 (95% CI: 0.22, 0.41).

In the sensitivity analysis, people of unknown ethnicity were re-categorized as White. There was a lower incidence in the BME compared with White populations in crude incidence (IRR = 0.64, 95% CI: 0.44, 0.94, $P=0.01$), but this was partly explained by the younger age-structure of the BME population, and once adjusted for age and sex the effect was reduced and non-significant at the 5% level (IRR = 0.81, 95% CI: 0.56, 1.18, $P=0.3$) (Table 2).

Prevalence

In 2013, the overall prevalence was 134.9 (95% CI: 121.3, 149.6). The prevalence among adults was 163.8 (95% CI: 147.2, 181.7)/million and among children (age <16 years) was 4.2 (95% CI: 0.5, 15.0) (Table 3). In analysis mutually adjusted for age, sex and ethnicity, prevalence was lower among women than among men (OR = 0.79, 95% CI: 0.64, 0.97, $P=0.027$), highest in the 70–84 age group (OR = 8.5, 95% CI: 5.7, 12.5 compared with the 16–39 age group, $P < 0.0001$), and lower in the BME than White population (OR = 0.57, 95% CI: 0.39, 0.84, $P=0.002$).

Mortality

One hundred and twenty of 462 patients died in 2049 person-years of follow-up, giving a mortality rate of 58.6/1000 person-years (Table 4). Mortality was 4.8% (95% CI: 3.2, 7.2%) at 30 days, 9.9% (95% CI: 7.5,

TABLE 2 Incidence of granulomatosis with polyangiitis 1997–2013 per million person-years

Demographic	Cases	Person-years	Crude incidence rate (95% CI)	Crude rate ratios (95% CI)	Adjusted rate ratios ^a (95% CI)	P-value ^b
Overall	462	39 286 088	11.8 (10.7, 12.9)			
Sex						
Male	262	19 518 443	13.4 (11.9, 15.2)	1	1	<0.0001
Female	200	19 767 549	10.1 (8.8, 11.6)	0.75 (0.62, 0.90)	0.67 (0.56, 0.81)	
Age group, years						
0–15	6	6 812 383	0.9 (0.4, 2.0)	0.2 (0.1, 0.6)	0.2 (0.1, 0.6)	<0.0001
16–39	42	11 758 023	3.6 (2.6, 4.8)	1	1	
40–54	100	8 825 359	11.3 (9.3, 13.8)	3.2 (2.2, 4.6)	3.1 (2.2, 4.4)	
55–69	190	6 875 272	27.6 (24.0, 31.9)	7.8 (5.6, 10.9)	6.8 (4.9, 9.6)	
70–84	112	4 113 670	27.2 (22.6, 32.8)	7.6 (5.3, 10.9)	6.4 (4.5, 9.1)	
85+	12	901 382	13.3 (7.6, 23.4)	3.7 (2.0, 7.1)	3.4 (1.8, 6.4)	
Ethnicity						
White	390	24 040 059	16.2 (14.7, 17.9)	1	1	<0.0001
BME	29	3 690 640	7.9 (5.5, 11.3)	0.48 (0.33, 0.70)	0.64 (0.44, 0.94)	
Unknown	43	11,555,389	3.7 (2.8, 5.0)	0.23 (0.17, 0.31)	0.30 (0.22, 0.41)	
Sensitivity analysis one with all unknown coded as White						
White	433	35 595 448	12.2 (11.1, 13.4)	1	1	0.3
BME	29	3 690 640	7.9 (5.5, 11.3)	0.64 (0.44, 0.94)	0.81 (0.56, 1.18)	

Cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES). ^aMutually adjusted for other variables in the model (sex, age group and ethnicity). ^bFrom mutually adjusted analysis using the likelihood ratio test. BME: Black/Minority Ethnic.

TABLE 3 Prevalence of granulomatosis with polyangiitis in 2013 per million person-years

Demographic	Cases	Denominator	Crude prevalence	Crude odds ratios (95% CI)	P-values	Adjusted odds ratios ^a (95% CI)	P-value ^b
Overall	359	2 661 668	134.9 (121.3, 149.6)				
Sex							
Male	189	1 311 314	144.1 (124.3, 166.2)	1		1	0.03
Female	170	1 350 349	125.9 (107.7, 146.3)	0.87 (0.71, 1.07)	0.201	0.79 (0.64, 0.97)	
Age group, years							
0–15	2	481 893	4.2 (0.50, 15.0)	0.1 (0.02, 0.4)	0.002	0.1 (0.02, 0.4)	<0.0001
16–39	33	811 940	40.6 (28.0, 57.1)	1		1	
40–54	83	583 600	142.2 (113.3, 176.3)	3.5 (2.3, 5.2)	<0.001	3.4 (2.3, 5.2)	
55–69	121	453 300	266.9 (221.5, 318.9)	6.6 (4.5, 9.7)	<0.001	6.1 (4.2, 9.0)	
70–84	106	262 348	404.0 (330.8, 488.7)	9.9 (6.7, 14.7)	<0.001	8.5 (5.7, 12.5)	
85+	14	68 587	204.1 (111.6, 342.5)	5.0 (2.7, 9.4)	<0.001	4.2 (2.2, 7.8)	
Ethnicity							
White	310	1 681 714	184.3 (164.4, 206.0)	1		1	<0.0001
BME	29	457 887	63.3 (42.4, 91.0)	0.34 (0.23, 0.50)	<0.001	0.46 (0.32, 0.68)	
Unknown	20	522 067	38.3 (23.4, 59.2)	0.21 (0.13, 0.33)	<0.001	0.22 (0.14, 0.35)	
If all unknown ethnicity, coded as White:							
White	330	2 203 781	149.7 (134.0, 166.8)	1		1	0.002
BME	29	457 887	63.3 (42.4, 91.0)	0.42 (0.29, 0.62)	<0.001	0.57 (0.39, 0.84)	

Cases ascertained from the Clinical Practice Research Datalink and Hospital Episode Statistics (CPRD-HES). ^aMutually adjusted for other variables in the model (sex, age group and ethnicity). ^bFrom mutually adjusted analysis using the likelihood ratio test. BME: Black/Minority Ethnic.

13.0%) at 90 days and 13.6% (95% CI: 10.8, 17.2%) at 1 year. Mortality was similar in males and females [hazard ratio (HR) = 0.8, 95% CI: 0.6, 1.2], higher with increasing age (HR for ≥85 years compared with the 16–39 age group 16.1, 95% CI: 3.6, 72.8, *P*-trend < 0.0001).

Mortality was highest in the group with unknown ethnicity (HR compared with Whites 1.8, 95% CI: 1.1, 3.0), intermediate in Whites, and appeared lowest in the BME group (HR = 0.5, 95% CI: 0.1, 2.0); however, there were only two deaths in this group. Mortality was higher in people

TABLE 4 Mortality of granulomatosis with polyangiitis 1997–2013 per thousand person-years

Demographic	Cases	Deaths	Years at risk	Crude mortality	Crude odds ratios (95% CI)	P-values	Adjusted odds ratios ^a (95% CI)	P-value ^b
Overall	462	120	2049	58.6				
Sex								
Male	262	76	1137	66.9	1		1	
Female	200	44	912	48.2	0.7 (0.5, 1.1)	0.12	0.8 (0.6, 1.2)	0.7
Age group, years								
0–15	6	0	16	0	–		–	
16–39	45	2	156	12.8	1	<0.0001	1	<0.0001
40–54	114	7	428	16.3	1.3 (0.3, 6.5)		1.2 (0.3, 5.9)	
55–69	224	36	837	43.0	3.6 (0.9, 15.1)		3.3 (0.8, 13.8)	
70–84	174	60	551	108.8	9.8 (2.4, 40.1)		7.2 (1.7, 29.7)	
85+	30	15	60	249.0	24.4 (5.5, 107)		16.1 (3.6, 72.8)	
White	390	95	1794	53.0	1	<0.0001	1	0.03
BME	29	2	115	17.4	0.3 (0.08, 1.3)		0.5 (0.1, 2.0)	
Unknown	43	23	141	163.2	2.9 (1.8, 4.5)		1.8 (1.1, 3.0)	
CPRD	319	62	1621	38.2	1		1	<0.0001
HES only	143	58	428	135.5	3.1 (2.2, 4.5)	<0.0001	2.3 (1.6, 3.4)	

Cases ascertained from the CPRD-HES. ^aMutually adjusted for other variables in the model (sex, age group and ethnicity and source of case ascertainment). ^bFrom mutually adjusted analysis, using the likelihood ratio test. CPRD: Clinical Practice Research Datalink; HES: Hospital Episode Statistics.

identified only in HES only compared with cases identified in CPRD with or without a HES diagnosis (HR = 2.3, 95% CI: 1.6, 3.4, $P < 0.0001$). This is shown in the Kaplan–Meier survival estimates for people with GPA presented separately by source of case ascertainment, which are shown in Fig. 2.

Estimated UK incidence

We estimate that at present each year in the UK there will be 700 new cases of GPA, of whom 95 will die within 12 months. We estimate that there are 8750 people living with GPA in the UK in 2016.

Sensitivity analysis (use of data from all CPRD practices)


We identified 574 incident cases of GPA during 1995–2014 in the whole CPRD (see supplementary Fig. S1, available at *Rheumatology* online). Similar to CPRD-HES, there was a slight male predominance (54.9% male) and a similar age at diagnosis [mean 58.6 (s.d. 15.8) years]. The estimated incidence was lower at 8.1 (95% CI: 7.5, 8.8)/million person-years. The effect of age and gender were similar (see supplementary Tables S2 and S3, available at *Rheumatology* Online). The incidence was stable throughout the period. The mortality rate was also lower: 125 patients of 574 died in 3002.2 person-years of follow-up, giving a mortality rate of 41.6/1000 person-years, with mortality 2.1% at 30 days, 4.0% at 90 days and 8.5% at 1 year.

Discussion

Main findings

Our estimate of the incidence of GPA in the UK is 11.8/million person-years, which is higher than previous

Fig. 2 Kaplan–Meier survival curve for granulomatosis with polyangiitis in the Clinical Practice Research Datalink



Hazard ratio 3.21 (95% CI: 2.23, 4.64), $P < 0.001$ (Schoenfeld's test to detect departure from non-proportional hazards; $P = 0.32$). CPRD: Clinical Practice Research Datalink; HES: Hospital Episode Statistics.

estimates. The incidence has been stable from 2000 onwards, is higher in men than in women and is highest in older age groups. The incidence was lower in the BME than White population in crude analyses, but this was partially explained by the different age and sex distribution of the BME population. The prevalence of GPA was 134.9/million in 2013, higher in men than women, and highest in the 70–85 age group. Prevalence was lower in BME than in White people, and this was again partially explained by

confounding by age and sex. Mortality among people with GPA was 14% at 1 year, and was significantly worse among those identified in hospital than among those identified in GP records.

Strengths

To our knowledge this is the first study that has combined general-population-based and hospital case ascertainment. Our comparator analysis with case ascertainment from primary care records (CPRD-only) shows that case ascertainment using both primary and secondary care is a more sensitive method, and that it allows identification of an important group of patients with the highest mortality. Compared with case ascertainment in secondary care only, this method is also more sensitive, and identifies a group of patients with lower mortality.

To our knowledge, this is one of the largest studies of GPA ever conducted. The largest previous studies both report cases identified prior to 2000 and identified cases using hospital discharge registers in Sweden ($n=1938$) and Finland ($n=492$) [6–8], which are difficult to compare with our study as they both report a rising incidence during their study periods, which is at least partially explained by increased recognition of the condition due to the introduction of routinely available ANCA-testing during the 1990s. The largest recent study was the previous CPRD study, which identified 295 incident cases [3]. Our analysis of 462 cases has given the analyses greater power, allowing estimates such as incidence and prevalence in the paediatric (<16 years) population. This study is also the first in the CPRD, and second in the UK, to include ethnicity, and provide predictions for planning health services for the BME population.

Limitations

The main limitation of this study is lack of power, which limits all studies of rare diseases. However, we have used the largest existing database of linked primary and secondary care records worldwide. Second, this study has limitations inherent in research using large databases of routinely collected healthcare information. In particular, the validity and date of each diagnosis could not be verified externally. However, the previous CPRD study examined the anonymized letters from 31 patients coded as G754, and the diagnosis of GPA was confirmed in 28 of those, giving a positive predictive value of 90% [3]. An additional 1 (4%) case had a diagnosis of microscopic polyangiitis, and in 2 (7%) the diagnosis could not be confirmed but it was likely they had some form of vasculitis. Our previous study, using multiple sources of case ascertainment to identify incident cases of ANCA-associated vasculitis [9], found searching inpatient discharges using ICD-10 code M313 identified 119 cases in our local hospital between 2007 and 2013. Of these, review of the medical notes confirmed a diagnosis of GPA in 102, giving a positive predictive value of 86%. A further 10 cases (8%) had a diagnosis of microscopic polyangiitis, and only 7 (6%) had no evidence of systemic vasculitis. In both instances, the number of missed cases could not be

estimated; however, we would expect that some patients were only ever coded as vasculitis and were missed by our search. It is most likely that our results are an underestimate of the true incidence and prevalence.

It is also possible that some prevalent cases may have been wrongly identified as incident, which would falsely increase our estimate of incidence. However, GP records should record previous significant diagnoses even in new registrations, and most relapses are in the first year after diagnosis, meaning that we will have excluded most prevalent cases from our incidence estimate by requiring 1 year of active follow-up prior to diagnosis. This method is the same as used previously [3], and has been validated in a range of other chronic conditions in the CPRD [4].

Fits in with other literature

Overall, our estimate of incidence was higher than that of previous studies, and we think this was due to the more sensitive strategy of case ascertainment. In the last 10 years in Europe, estimates (which have been in studies of adults only) have ranged from 4.9/million adult-years in a hospital-based study in Southern Spain to 11.3/million adult-years in a hospital-based study in the UK (Norfolk) [6, 10–14], although it is unclear whether differences in methods of case ascertainment or true geographic differences account for the variation. Our incidence in the CPRD-only population of 8.1 (95% CI: 7.5, 8.8)/million person-years was very similar to that of the previous CPRD study conducted 1990–2005, in which the incidence was estimated to be 8.3 (95% CI: 7.5, 9.4) [3], and this shows how incidence can be underestimated unless cases are ascertained from secondary as well as primary care. Our findings show a lower incidence in women compared with in men (which is in keeping with many [3, 10–13, 15], but not all [6, 16, 17], previous smaller studies) and confirm the age group with the highest incidence to be ~60–70 years [3, 13].

The incidence rose rapidly in both CPRD and HES databases in the first 5 years after inception of each database (1987 in the CPRD and 1997 in HES)—which is a finding common to database studies in other conditions and may reflect data collection practices [18]. After these times, each database showed a stable incidence. We did not find evidence of a cyclical pattern of incidence, which has been seen in other studies [10].

A recent study has shown that CPRD-HES contain the same ethnic mix as the UK in the 2011 census, and that they provide reliable records of self-reported ethnicity [19]. Reliability is much higher for White vs BME differentiation than between BME ethnic groups, so we treated ethnicity as a binary variable (White vs BME) for most analyses. Frequency of ethnicity recording also increased after 1 April 2006, when recording ethnicity was introduced to the UK National Health Service Quality and Outcomes Framework; however, this only accounts for 22 of our 462 incident cases. We therefore have incomplete ethnicity data: available for 90.7% of cases, and only 76.8% of the denominator population. We used a

worst-case scenario approach and re-coded the unknown group to White. This approach also reflects the 2011 census results, resulting in 86.2% of the denominator population being White compared with 85.2% in the 2011 census. We found that the incidence was lower in BME compared with Whites—but this was not statistically significant at the 5% level. This is similar to our findings in a local hospital cohort of people with all types of ANCA-associated vasculitis (and complete ethnicity data), where the IRR adjusted for age and sex for BME compared with White people was 0.7, 95% CI: 0.3, 1.5, $P=0.3$) [19]. However, we found the prevalence of GPA was lower in BME than in White populations, even after adjustment for age and sex (adjusted OR = 0.6, $P=0.004$). It is possible that a survival bias explains our findings if the disease is more severe in the BME population, or that we only captured the more severe end of the spectrum for this group; however, we were unable to analyse the mortality rate difference between the White and BME groups, due to small numbers as there were only two deaths (among 29 patients) in the BME group. If the UK population ages as predicted in the coming years, and the age structure of the BME and White populations become more similar, we would expect to see an increase in the number of incident cases of GPA, and an increasing proportion from BME ethnic groups.

Our estimate of mortality at 1 year using CPRD-HES was higher than our estimate of mortality for the CPRD only, and as high as reported estimates from hospital studies. Increased mortality in cases ascertained from HES compared with CPRD has been found in other conditions [20], which shows the importance of ascertaining cases from secondary care data in addition to GP records, as patients ascertained in hospital are more likely to be sicker. The lowest reported 1-year mortality of 1–7% comes from registry studies, or highly selective (tertiary-referral) centres [21, 22], where patients also have the lowest average age. An intermediate level of 5–11% is found in community studies [12, 23]. And the highest mortality of 14–21% is reported from hospitals [7, 9, 24, 25] and clinical trials of patients with severe disease [26]. The highest mortality is in the first year after diagnosis; we did not find a bimodal increase in mortality after 8 years as reported by Luqmani and colleagues [23]. A recent systematic review of mortality confirms that ANCA-associated vasculitis has the highest mortality of the autoimmune rheumatic conditions [27].

Conclusion

Our findings suggest that the incidence of GPA is stable over time, higher in men than in women, and highest in older people. We estimate that there will be 700 incident cases in the UK during 2016. Despite improvements in medical care, mortality is high, and higher than in other autoimmune rheumatic conditions. We predict that 95 people in the UK will die this year within 12 months of their GPA diagnosis. Estimates that do not include hospital data will underestimate both incidence and mortality.

Funding: This work was supported by Vasculitis UK (Charity).

Disclosure statement: The authors have declared no conflicts of interest.

Supplementary data

Supplementary data are available at *Rheumatology Online*.

References

- 1 Ntatsaki E, Watts RA, Scott DGI. Epidemiology of ANCA-associated vasculitis. *Rheum Dis Clin* 2014;36:447–61.
- 2 Herrett E, Gallagher AM, Bhaskaran K *et al*. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol* 2015;44:827–36.
- 3 Watts RA, Al-Taiar A, Scott DGI *et al*. Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database. *Arthritis Rheum* 2009;61:1412–6.
- 4 Lewis JD, Bilker WB, Weinstein RB *et al*. The relationship between time since registration and measured incidence rates in the General Practice Research Database. *Pharmacoepidemiol Saf* 2005;14:443–51.
- 5 Office for National Statistics. Population Estimates for UK, England and Wales, Scotland and Northern Ireland. 2015. <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland> (Accessed 30th April 2016).
- 6 Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M. Incidence of Wegener's granulomatosis in Finland 1981–2000. *Clin Exp Rheumatol* 2008;26:S81–5.
- 7 Takala JH, Kautiainen H, Leirisalo-Repo M. Survival of patients with Wegener's granulomatosis diagnosed in Finland in 1981–2000. *Scand J Rheumatol* 2010;39:71–6.
- 8 Knight A, Ekbohm A, Brandt L *et al*. Increasing incidence of Wegener's granulomatosis in Sweden, 1975–2001. *J Rheumatol* 2006;33:2060–3.
- 9 Pearce FA, Lanyon PC, Grainge MJ *et al*. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. *Rheumatology* 2016;55:1656–63.
- 10 Watts RA, Mooney J, Skinner J *et al*. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. *Rheumatology* 2012;51:926–31.
- 11 Watts RA, Gonzalez-Gay MA, Lane SE *et al*. Geoeconomics of systemic vasculitis: comparison of the incidence in two regions of Europe. *Ann Rheum Dis* 2001;60:170–2.
- 12 Mohammad AJ, Jacobsson LTH, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg–Strauss syndrome and polyarteritis nodosa. *Rheumatology* 2009;48:1560–5.
- 13 Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. *Arthritis Rheum* 2000;43:2481–7.

- 14 Herlyn K, Hellmich B, Gross WL *et al.* Stable incidence of systemic vasculitides in Schleswig-Holstein, Germany. *Dtsch Arztebl Int* 2008;105:355–61.
- 15 Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. *Intern Med J* 2008;38:816–23.
- 16 O'Donnell JL, Stevanovic VR, Frampton C *et al.* Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. *Intern Med J* 2007;37:242–6. doi:10.1111/j.1445-5994.2006.01297.x
- 17 Hissaria P, Cai FZJ, Ahern M *et al.* Wegener's granulomatosis: epidemiological and clinical features in a South Australian study. *Intern Med J* 2008;38:776–80.
- 18 Iyen-Omofoman B, Hubbard RB, Smith CJP *et al.* The distribution of lung cancer across sectors of society in the United Kingdom: a study using national primary care data. *BMC Public Health* 2011;11:857.
- 19 Mathur R, Bhaskaran K, Chaturvedi N *et al.* Completeness and usability of ethnicity data in UK-based primary care and hospital databases. *J Public Health* 2014;36:684–92.
- 20 Crooks C, Card T, West J. Defining upper gastrointestinal bleeding from linked primary and secondary care data and the effect on occurrence and 28 day mortality. *BMC Health Serv Res* 2012;12:392.
- 21 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R *et al.* No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. *Rheumatology* 2002;41:540–9.
- 22 Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. *Rheumatology* 2002;41:572–81.
- 23 Luqmani R, Suppiah R, Edwards CJ *et al.* Mortality in Wegener's granulomatosis: a bimodal pattern. *Rheumatology* 2011;50:697–702. doi:10.1093/rheumatology/keq351
- 24 Lane SE, Watts RA, Shepstone L *et al.* Primary systemic vasculitis: clinical features and mortality. *QJM* 2005;98:97–111.
- 25 Lai Q-Y, Ma T-T, Li Z-Y *et al.* Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. *J Rheumatol* 2014;41:1849–55.
- 26 Flossmann O, Berden A, de Groot K *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011;70:488–94.
- 27 Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. *Lancet* 2013;382:797–808.